Famciclovir for Treatment of Herpesvirus Infections

@article{Luber1996FamciclovirFT,
  title={Famciclovir for Treatment of Herpesvirus Infections},
  author={Andrew D. Luber and John F. Flaherty},
  journal={Annals of Pharmacotherapy},
  year={1996},
  volume={30},
  pages={978 - 985}
}
OBJECTIVE: To discuss the antiviral activity, pharmacokinetics, clinical efficacy, and adverse effect profile of famciclovir, the oral prodrug of penciclovir (PCV), and to compare these features of famciclovir with those of acyclovir in the treatment of herpesvirus infections. DATA SOURCES: Literature was identified by MEDLINE search, and abstracts from recent meetings were included where relevant. Data provided by the manufacturer were also used. STUDY SELECTION: Data regarding antiviral… 

Figures and Tables from this paper

Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster

Oral acyClovir, valacyclovir and famciclovir are efficacious and safe for the treatment of the first episode and recurrent genital herpes and are useful as suppressive therapy for individuals with frequent genital herpes recurrences.

Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections

The present Drug Annotation focuses on the helicase–primase inhibitor pritelivir currently in development for the treatment of acyclovir-resistant HSV infections and describes how a change of the molecular target afforded improvement of the shortcomings of nucleoside analogs.

Valacyclovir in the treatment of genital herpes and herpes zoster

  • D. Baker
  • Medicine
    Expert opinion on pharmacotherapy
  • 2002
Valacyclovir is well tolerated, with convenient dosing frequencies for the treatment of genital herpes or herpes zoster, it also has the option for use as a short course therapy in the episodic treatment of recurrent genital herpes, all of which are important benefits in the management of these conditions.

Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and Other Viral Infections

Valacyclovir is safe and effective in the therapy of patients with herpes simplex and herpes zoster and may be useful in other viral infections.

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients

Intermittent famciclovir prophylaxis is effective and safe in preventing herpes zoster development and can markedly reduce the duration of oral medicine treatment compared with continuous acyclovir proPHylaxis.

Valacyclovir for the treatment of genital herpes

Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster, and the less frequent dosing regimen makes it an attractive option in the treatment of genital herpes and other viral infections, and may contribute to increased patient adherence to therapy.

Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and other Viral Infections

The pharmacology, pharmacokinetics, and clinical efficacy of valacyclovir for the treatment of herpes simplex, herpes zoster, and other viral infections are described.

Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis.

Both the suction blister technique and microdialysis showed that penciclovir reaches the skin in concentrations sufficient to inhibit herpes virus replication.

Clinical management of selected oral fungal and viral infections during HIV-disease.

  • P. Reichart
  • Medicine, Biology
    International dental journal
  • 1999
Current possibilities of management of selected fungal and viral oral opportunistic infections including oral candidiasis, herpes simplex type 1 and 2-related lesions, oral hairy leukoplakia, and oral lesions associated with human papilloma viruses are described.

References

SHOWING 1-10 OF 42 REFERENCES

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Oral aciclovir has prevented recurrence of HSV genital or orofacial infections during suppressive therapy in > 70% of immunocompetent patients in most clinical trials and appears to offer partial protection from invasive CMV disease in CMV-seropositive bone marrow transplant recipients.

Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern

Both compounds were highly selective antiviral agents with minimal effects on a wide range of representative, proliferating human cells, and the mechanism of action of penciclovir has been investigated.

Safety of famciclovir in patients with herpes zoster and genital herpes

Safety data from the analysis of 13 completed clinical studies demonstrate that famciclovir is tolerated well by patients with either herpes zoster or genital and has a safety profile comparable to that of placebo.

Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir

The efficient entrapment of the active moiety can account for the markedly better antiviral activity of penciclovir than acyclovir when infected cell cultures were treated for a short time.

Efficacy of oral acyclovir treatment of acute herpes zoster.

No significant hastening of rash healing was seen in those who started therapy later than 48 hours after the onset of rash, and acyclovir produced no effects on the frequency or severity of post-herpetic neuralgia.

Pharmacokinetics of Famciclovir in Single and Repeat Administration in Humans

There was no evidence for drug accumulation and for alternation of the pharmacokinetics of famciclovir by the repeat dose regimen studied, and the urinary excretions and total metabolites determined were statistically not different between Days 1 and 7, and also between Day 1 and through the administration period.

Pharmacokinetics of acyclovir after intravenous and oral administration.

Acyclovir half-life (T1/2 beta) and total body clearance (Cltot) are influenced significantly by renal function, and dosage adjustments should be made for patients with impaired renal function; therefore dosage adjustments based on Clcr will compensate for age-related changes in renal function.

New antivirals with activity against varicella‐zoster virus

  • J. Gnann
  • Medicine, Biology
    Annals of neurology
  • 1994
Efforts are underway to develop new drugs that have improved activity against varicella‐zoster virus as well as more favorable pharmacokinetic properties, to develop an orally administered antiviral drug that will accelerate the events of cutaneous healing aswell as reduce the frequency and severity of post‐herpetic neuralgia.

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

The data suggest that penciclovir or its oral form, famciclavir, may have clinical utility in the treatment of chronic hepatitis B virus infection.